The Social Security Administration Commissioner Frank Bisignano confirmed that while the program will last another 90 years, its main trust fund is projected to be depleted by 2032. This insolvency would force automatic benefit cuts, estimated at around 22%, as payouts would be limited to incoming payroll tax revenue. The program faces financial strain due to demographic shifts, with fewer workers supporting more retirees. Policymakers are urged to consider reforms, though specific changes to benefits or taxes were not detailed by Bisignano.
The Social Security program's future was discussed alongside Pluang's Financials sector data as of Oct 14, 2026 05:41 WIB. Among 118 priced US Financial stocks on Pluang, 51 rose and 67 fell. Notable movers include NatWest Group plc at USD 17.66 with a 2.44% gain and Nu Holdings Ltd at USD 15.62 with a 2.44% loss.
ZenaTech announced a 27.1% organic revenue growth in its Drone as a Service (DaaS) operations in 2026, driven by integrating AI and drones into surveying and inspection workflows. The company expects Q3 2026 revenues between C$13.4 million and C$14.8...
Nvidia CEO Jensen Huang has reaffirmed his long-standing forecast that global spending on AI infrastructure will surge to between $3 trillion and $4 trillion by 2030. This projection highlights the massive growth potential in the AI sector, driven by...
Targa Resources Corp. announced a quarterly cash dividend of $1.25 per common share for Q3 2026, payable on November 17, 2026, to shareholders of record as of October 30, 2026. The company will release its Q3 2026 financial results before market open...
Bitcoin recently rallied above $85,000 but now shows potential signs of forming an October bottom amid market uncertainty. Despite 71.04% of Bitcoin supply being profitable, nearly 29% remains at a loss, indicating ongoing market stress. Large liquid...
On October 13, 2026, several stocks including Adlai Nortye, Omada Health, Syndax Pharmaceuticals, Six Flags, and Immunic saw significant declines. Syndax dropped 15.7% after its Phase 2 trial for a lung disease drug failed, leading to halted developm...
